Delivery Order SPE2DB22D2108-SPE2DB24FU2XP

Award Date 12/14/23
Potential Completion Date 12/15/23
Potential Value $4.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Oxcarbazepine 300 mg/5 ml suspension in 250 ml bottles to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,762.42, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an ultimate completion date of December 27, 2023 and is a firm fixed-price delivery order. This award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA, valued at up...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,259.73, is for the delivery of oxcarbazepine 300 mg/5 ml suspension, a generic anticonvulsant medication, with a completion date of February 25, 2025. The contract is a firm-fixed-price delivery order, without any set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,135.08, is for the delivery of a specific pharmaceutical product, OXCARBAZEPINE 300 MG/5 ML SUSP 250ML, with an ultimate completion date of May 30, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with the DLA....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4567260047 - Oxcarbazepine 300 mg/5 ml suspension in 250 ml bottles. The contract has a ceiling value of $1,364.06 and runs through February 14, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,090.18 Firm Fixed Price Delivery Order is for the supply of 4,566,615,636 units of OXCARBAZEPINE 600 MG TABLET 500S, with a completion date of December 5, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of 4566734673 OXCARBAZEPINE ER 600 MG TABLET 100S. The contract has a ceiling value of $5,945.20 and an ultimate completion date of December 17, 2024. This award is a delivery order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, identified as SPE2DB22D2007|SPE2DB24FJ2KG, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4564558250 - OXCARBAZEPINE 300 MG/5 ML SUSP 250ML, a pharmaceutical product, with a ceiling value of $4,221.31 and an ultimate completion date of May 10, 2024. The contract is a Delivery Order and is priced as a Firm Fixed Price. It is not designated as a set-aside contract....
This federal contract award, with ID SPE2DB22D1202|SPE2DB25FUJK4, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,482.78 firm fixed-price delivery order is for the supply of 4566420572 - OXCARBAZEPINE 300 MG TABLET 100S. The contract has an ultimate completion date of November 14, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
This federal contract award is for the delivery of Trileptal 300 mg/5 ml suspension in 250 ml bottles to the Defense Logistics Agency (DLA). The contract, valued at $2,063.12, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price delivery order, without any set-aside designation, and has an ultimate completion date of January 5, 2022. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc. and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $3,201.96, is for the delivery of Trileptal 300 mg/5 ml suspension in 250 ml bottles. This is a firm fixed-price delivery order contract with a completion date of May 11, 2023. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up...
  • SPE2DB22D2108
    Indefinite Delivery Contract
  • SPE2DB22D2108-SPE2DB24FU2XP
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of Oxcarbazepine 300 mg/5 ml suspension in 250 ml bottles. The $4,104.42 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition.

Generated 5/13/25, 10:18 AM